Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | TGM2 | P21980 | 1/20 | 0.66 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.65 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.62 |
| ▸ | GSK3A | P49840 | 2/20 | 0.62 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | KRAS | P01116 | 4/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | HINT1 | P49773 | 1/20 | 0.59 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidazole SCHEMBL1092329 | 0.94 | TGM2 (0.71) | NT5ETGM2IMPDH2IMPDH1GSK3A | |
| Guanosine Triphosphate SCHEMBL22658532 | 0.93 | TGM2 (0.70) | NT5ETGM2IMPDH2IMPDH1GSK3A | |
| E626 SCHEMBL9980018 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL21163348 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL18763818 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL18759049 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL21803790 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL13497991 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL20677331 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| E626 SCHEMBL20276926 | 0.91 | NT5E (0.83) | NT5ETGM2IMPDH2IMPDH1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306779-A | R-configuration-containing initial capping oligonucleotide primer and synthesis method thereof | 上海科泽永欣生物科技有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-119241624-A | Initial capping oligonucleotide primer containing HNA structure and preparation method and application thereof | 上海科泽永欣生物科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119306779-A | R-configuration-containing initial capping oligonucleotide primer and synthesis method thereof | 上海科泽永欣生物科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119241624-A | Initial capping oligonucleotide primer containing HNA structure and preparation method and application thereof | 上海科泽永欣生物科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-10696709-B2 | Phosphotriazole MRNA 5′-end cap analogs, composition comprising the same, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule, protein or peptide | UNIWERSYTET WARSZAWSKI (PL) | 2020-06-30 | — | — | US | disclosed |
| EP-3484907-B1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | UNIV WARSZAWSKI (PL) | 2020-05-13 | — | — | EP | disclosed |
| US-20200055891-A1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2020-02-20 | — | — | US | disclosed |
| EP-3484907-A1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | Uniwersytet Warszawski (PL) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018015845-A1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2018-01-25 | — | — | WO | disclosed |
| US-8519110-B2 | mRNA cap analogs | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2297175-B1 | MRNA CAP ANALOGS | UNIV WARSZAWSKI (PL) | 2013-08-07 | — | — | EP | disclosed |
| US-8093367-B2 | Preparation and isolation of 5′ capped mRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110092574-A1 | mRNA Cap Analogs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-21 | — | — | US | disclosed |
| EP-2297175-A2 | MRNA CAP ANALOGS | Uniwersytet Warszawski (PL) | 2011-03-23 | — | — | EP | disclosed |
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100261231-A1 | Dinucleotide MRNA CAP Analogs | LIFE TECHNOLOGIES CORPORATION, A DELAWARE CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009149253-A2 | MRNA CAP ANALOGS | UNIWERSYTET WARSZAWSKI (PL) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009058911-A2 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| EP-2049665-A2 | DINUCLEOTIDE MRNA CAP ANALOGS | Applera Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016473-A2 | DINUCLEOTIDE MRNA CAP ANALOGS | APPLERA CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | RNGTT, RNMT, NSUN2 | NT5E 795/4885TGM2 3263/4885IMPDH2 1203/4885 |
| US-10696709-B2 | Phosphotriazole MRNA 5′-end cap analogs, composition comprising the same, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule, protein or peptide | RNGTT, RNMT, NSUN3 | NT5E 1027/4885TGM2 3265/4885IMPDH2 1459/4885 |
| US-20100261231-A1 | Dinucleotide MRNA CAP Analogs | RNGTT, RNMT, NSUN2 | NT5E 343/4885TGM2 3982/4885IMPDH2 509/4885 |
| US-20200055891-A1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | RNGTT, RNMT, NSUN3 | NT5E 867/4885TGM2 3588/4885IMPDH2 1446/4885 |
| US-20110092574-A1 | mRNA Cap Analogs | RNMT, RNGTT, NSUN2 | NT5E 2213/4885TGM2 4619/4885IMPDH2 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.